3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Other hematologic neoplasm
1
Lymphoid
1
Dermatologic
1
CNS
1
Conditions
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Recurrence
1
Neuroblastoma
1
Neoplasms
1
Melanoma
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Leukemia, B-Cell
1
Leukemia
1
Glioma
1
Ependymoma
1
Interventions
Filgrastim
11
Temozolomide
9
Melphalan
9
Cyclophosphamide
9
Radiotherapy
7
Busulfan
7
Magnetic Resonance Spectroscopy
6
Rituximab
5
Psychiatric Rehabilitation
5
Methotrexate
5
Etoposide
5
Cytarabine
5
Carboplatin
5
sargramostim
4
fludarabine
4
etoposide phosphate
4
Thiotepa
4
Nivolumab
4
Methylprednisolone
4
Flow Cytometry
4
Alemtuzumab
4
Vincristine
3
Topotecan
3
Specimen Handling
3
Peripheral Blood Stem Cell Transplantation
3
Pemetrexed
3
Granulocyte Colony-Stimulating Factor
3
Early Intervention, Educational
3
Drug Therapy
3
Dexamethasone
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma
×
bempegaldesleukin
×
CNS
×
Clear all
NCT04730349
2023-03-24
PIVOT IO 020
Bristol-Myers Squibb
Phase 1/2
Terminated
15 enrolled
14 charts